State of Alaska Department of Revenue decreased its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,341 shares of the biopharmaceutical company’s stock after selling 73 shares during the period. State of Alaska Department of Revenue’s holdings in Regeneron Pharmaceuticals were worth $4,981,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Rehmann Capital Advisory Group raised its stake in Regeneron Pharmaceuticals by 1,700.0% during the 3rd quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 68 shares in the last quarter. Signaturefd LLC raised its stake in Regeneron Pharmaceuticals by 123.8% during the 2nd quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 198 shares in the last quarter. Flagship Harbor Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $159,000. Columbia Asset Management bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $196,000. Finally, Ingalls & Snyder LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $204,000. 67.20% of the stock is currently owned by institutional investors and hedge funds.

REGN opened at $408.63 on Monday. Regeneron Pharmaceuticals Inc has a one year low of $281.89 and a one year high of $416.49. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.30 and a current ratio of 4.04. The firm has a market capitalization of $43.24 billion, a PE ratio of 30.47, a PEG ratio of 1.72 and a beta of 1.14.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 EPS for the quarter, topping the Zacks’ consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a return on equity of 30.24% and a net margin of 28.24%. The company had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the previous year, the business earned $3.99 EPS. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. On average, research analysts forecast that Regeneron Pharmaceuticals Inc will post 18.88 EPS for the current year.

Several analysts have weighed in on the company. BidaskClub raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 7th. Cowen reaffirmed a “hold” rating and set a $385.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, January 7th. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 5th. Guggenheim raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $461.00 target price on the stock in a research note on Friday, January 4th. Finally, ValuEngine raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 15th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $404.11.

In related news, Director Joseph L. Goldstein sold 1,791 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, January 10th. The stock was sold at an average price of $410.00, for a total value of $734,310.00. Following the transaction, the director now directly owns 14,114 shares in the company, valued at approximately $5,786,740. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Christopher R. Fenimore sold 1,848 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, December 20th. The stock was sold at an average price of $358.97, for a total value of $663,376.56. Following the completion of the transaction, the vice president now owns 9,871 shares in the company, valued at $3,543,392.87. The disclosure for this sale can be found here. Insiders sold a total of 3,645 shares of company stock worth $1,399,980 in the last three months. Company insiders own 12.42% of the company’s stock.

WARNING: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/state-of-alaska-department-of-revenue-sells-73-shares-of-regeneron-pharmaceuticals-inc-regn/2744834.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: What is a Roth IRA?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.